1401 related articles for article (PubMed ID: 23707169)
1. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
2. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
6. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
Stebbings R; Février M; Li B; Lorin C; Koutsoukos M; Mee E; Rose N; Hall J; Page M; Almond N; Voss G; Tangy F
PLoS One; 2012; 7(11):e50397. PubMed ID: 23226275
[TBL] [Abstract][Full Text] [Related]
8. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
Leroux-Roels G; Bourguignon P; Willekens J; Janssens M; Clement F; Didierlaurent AM; Fissette L; Roman F; Boutriau D
Clin Vaccine Immunol; 2014 Mar; 21(3):302-11. PubMed ID: 24391139
[TBL] [Abstract][Full Text] [Related]
10. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
Niu L; Termini JM; Kanagavelu SK; Gupta S; Rolland MM; Kulkarni V; Pavlakis GN; Felber BK; Mullins JI; Fischl MA; Stone GW
Vaccine; 2011 Mar; 29(11):2110-9. PubMed ID: 21241732
[TBL] [Abstract][Full Text] [Related]
12. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.
Boaz MJ; Waters A; Murad S; Easterbrook PJ; Vyakarnam A
J Immunol; 2002 Dec; 169(11):6376-85. PubMed ID: 12444145
[TBL] [Abstract][Full Text] [Related]
13. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness.
Dybul M; Mercier G; Belson M; Hallahan CW; Liu S; Perry C; Herpin B; Ehler L; Davey RT; Metcalf JA; Mican JM; Seder RA; Fauci AS
J Immunol; 2000 Aug; 165(3):1685-91. PubMed ID: 10903780
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.
Herasimtschuk A; Downey J; Nelson M; Moyle G; Mandalia S; Sikut R; Adojaan M; Stanescu I; Gotch F; Imami N
Vaccine; 2014 Dec; 32(51):7005-7013. PubMed ID: 25454870
[TBL] [Abstract][Full Text] [Related]
15. The expansion ability but not the quality of HIV-specific CD8(+) T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors.
López M; Peris A; Soriano V; Lozano S; Vicario JL; Rallón NI; Restrepo C; Benito JM
Immunology; 2011 Nov; 134(3):305-13. PubMed ID: 21978000
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
17. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.
Climent N; Munier S; Piqué N; García F; Pavot V; Primard C; Casanova V; Gatell JM; Verrier B; Gallart T
Vaccine; 2014 Oct; 32(47):6266-76. PubMed ID: 25240755
[TBL] [Abstract][Full Text] [Related]
18. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
Ondondo BO; Yang H; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Rowland-Jones SL; Hanke T; McMichael AJ; Dorrell L
Eur J Immunol; 2006 Oct; 36(10):2585-94. PubMed ID: 17013989
[TBL] [Abstract][Full Text] [Related]
19. No major differences in the functional profile of HIV Gag and Nef-specific CD8+ responses between long-term nonprogressors and typical progressors.
López M; Soriano V; Lozano S; Ballesteros C; Cascajero A; Rodés B; De La Vega E; González-Lahoz J; Benito JM
AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1185-95. PubMed ID: 18729773
[TBL] [Abstract][Full Text] [Related]
20. Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.
Nakiboneka R; Mugaba S; Auma BO; Kintu C; Lindan C; Nanteza MB; Kaleebu P; Serwanga J
Vaccine; 2019 Jan; 37(1):113-122. PubMed ID: 30459072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
